CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
We received an updated WNV package insert; please note the manufacturer and license number has been ...